



First Order of New 4D Imaging and Virtual Simulation System

C-RAD AB with its three fully owned subsidiaries and three international sales companies are all active in the field of radiation therapy with a focus on patient positioning and patient monitoring. Cyrpa is an innovative company specialized in laser based patient positioning in radiation therapy. C-RAD received the first order of the unique product combination of 4D Imaging and Virtual Simulation.

Part of the agreement with Cyrpa is to merge the sales organizations. In Italy the company TecnoSan S.a.s. has newly been appointed as the distributor for C-RAD. TecnoSan S.a.s. is distributing the Cyrpa product portfolio since 2012.

The first system of the unique product combination for 4D Imaging and Virtual Simulation based on the C-RAD Software Platform has been sold by TecnoSan to a hospital in Bolzano. The same customer bought a Catalyst System as well for the treatment room. Installation will take place in August.

All systems for Virtual Simulation and 4D Imaging sold by C-RAD and Cyrpa will be delivered with the C-RAD Software Platform.

Tim Thurn, CEO, C-RAD AB:

"We are very satisfied with this positive result. First of all it is a fantastic start with our new distributor in the 3rd largest RT Market in Europe. Secondly this sale confirms that customers see the strong advantages of combining Virtual Simulation and 4D Imaging. Such a solution is offered only by C-RAD and Cyrpa."

Mattia Dell'Orsola, Sales Manager, TecnoSan S.a.s

"It is a great pleasure for us to sell and market the C-RAD solutions in the Italian territory. We believe that by working together, we can provide very high quality products for our customers and we can further develop our market position in Italy."

About Tecnosan

Successfully operating in Italy since its foundation in 1985, Tecnosan offers an extensive range of products and solutions in the areas of radiation therapy, nuclear medicine and environmental monitoring.

As a distributor of prestigious international brands, Tecnosan operates across the Italian territory with highly qualified staff which assures a precise and competent service.

For more information on Tecnosan, please visit http://tecnosan.it/en/

About Cyrpa:

CYRPA, established in 2010 in Belgium, is a company specialized in innovative solutions in the radiotherapy field.



Founded by technical experts and an innovation investment fund, CYRPA products are currently distributed in 22 countries on mainland Europe but also in the USA, Latin America, Africa and Asia.

In 2011 CYRPA launched its « HIT » product range (High Impact Technology): laser systems used for patient-positioning during virtual simulation and radiotherapy treatment. The HIT systems include two major innovations: double-diode for each laser line, and the SmartPhantom, a device that allows high precision automatic calibration of the laser system in the CT room. CYRPA is the only positioning laser manufacturer that guarantees an accuracy of 0.1mm.

CYRPA's aim is to offer quality solutions in radiotherapy that provide higher precision for the patient and more safety for the medical staff.

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 24 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel^{TM,} started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.

For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com